{"DataElement":{"publicId":"7247366","version":"1","preferredName":"Immunotherapeutic Agent Related Adverse Event Rheumatologic Disorder Present Type","preferredDefinition":"Information related to the type of rheumatologic disorder immunotherapeutic related adverse event that is present.","longName":"7247365v1.0:7247334v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"7247365","version":"1","preferredName":"Immunotherapeutic Agent Relationship Adverse Event Rheumatologic Disorder Present","preferredDefinition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system._A state of connectedness between people, objects, or events; to be associated or connected with something._Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._Inflammatory and degenerative diseases of connective tissue structures, such as arthritis._Being or existing in a specified place or at the specified time.","longName":"6955286v1.0:7247363v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6955286","version":"1","preferredName":"Immunotherapeutic Agent Relationship Adverse Event","preferredDefinition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system.:A state of connectedness between people, objects, or events; to be associated or connected with something.:Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","longName":"C308:C25648:C41331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapeutic Agent","conceptCode":"C308","definition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93EC8B94-DB7D-03ED-E053-F662850AFC99","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7247363","version":"1","preferredName":"Rheumatologic Disorder Present","preferredDefinition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.:Being or existing in a specified place or at the specified time.","longName":"C27204:C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatologic Disorder","conceptCode":"C27204","definition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36B54E2-8CE4-21C0-E053-F662850A2A2C","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36B54E2-8CF5-21C0-E053-F662850A2A2C","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"MORENOC","dateModified":"2020-07-01","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7247334","version":"1","preferredName":"Immunotherapeutic Related Adverse Event Rheumatologic Disorder Type","preferredDefinition":"The type of rheumatologic disorder immunotherapeutic related adverse event.","longName":"7247334v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Arthritis","valueDescription":"Arthritis","ValueMeaning":{"publicId":"3292693","version":"1","preferredName":"Arthritis","longName":"3292693","preferredDefinition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthritis","conceptCode":"C2883","definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEA65AE0-D99F-3EBD-E040-BB89AD431EBC","latestVersionIndicator":"Yes","beginDate":"2011-10-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A368E683-674C-6973-E053-F662850A6DFC","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Guillain-Barre syndrome","valueDescription":"Guillain-Barre syndrome","ValueMeaning":{"publicId":"6061744","version":"1","preferredName":"Guillain-Barre syndrome","longName":"6061744","preferredDefinition":"A disorder characterized by the body's immune system attacking the peripheral nervous system causing ascending paralysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guillain-Barre Syndrome, CTCAE","conceptCode":"C143231","definition":"A disorder characterized by the body's immune system attacking the peripheral nervous system causing ascending paralysis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6482A7F1-50AD-582C-E053-F662850A7D99","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-02-05","modifiedBy":"ONEDATA","dateModified":"2018-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A368E683-6756-6973-E053-F662850A6DFC","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Myasthenia gravis","valueDescription":"Myasthenia Gravis","ValueMeaning":{"publicId":"3143924","version":"1","preferredName":"Myasthenia Gravis","longName":"3143924","preferredDefinition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness.  It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myasthenia Gravis","conceptCode":"C60989","definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167B9F7-3DD6-C748-E040-BB89AD432898","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A368E683-6760-6973-E053-F662850A6DFC","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2943908","version":"1","preferredName":"Vasculitis","longName":"2943908","preferredDefinition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener's granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742B257F-AAE1-95B9-E040-BB89AD4354AE","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A368E683-676A-6973-E053-F662850A6DFC","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Other rheumatologic condition","valueDescription":"Other Rheumatologic Disorder","ValueMeaning":{"publicId":"7247335","version":"1","preferredName":"Other Rheumatologic Disorder","longName":"7247335","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rheumatologic Disorder","conceptCode":"C27204","definition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A368E683-6777-6973-E053-F662850A6DFC","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A368E683-6790-6973-E053-F662850A6DFC","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A368E683-6735-6973-E053-F662850A6DFC","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"MORENOC","dateModified":"2020-07-01","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Specify Rheumatologic irAE","type":"Preferred Question Text","description":"Specify Rheumatologic irAE","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Specify irAE","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36B16BD-2073-1ECF-E053-F662850AB6D2","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"MORENOC","dateModified":"2020-11-19","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}